Vahidfar, N.; Farzanehfar, S.; Abbasi, M.; Mirzaei, S.; Delpassand, E.S.; Abbaspour, F.; Salehi, Y.; Biersack, H.J.; Ahmadzadehfar, H.
Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC. Cancers 2022, 14, 1914.
https://doi.org/10.3390/cancers14081914
AMA Style
Vahidfar N, Farzanehfar S, Abbasi M, Mirzaei S, Delpassand ES, Abbaspour F, Salehi Y, Biersack HJ, Ahmadzadehfar H.
Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC. Cancers. 2022; 14(8):1914.
https://doi.org/10.3390/cancers14081914
Chicago/Turabian Style
Vahidfar, Nasim, Saeed Farzanehfar, Mehrshad Abbasi, Siroos Mirzaei, Ebrahim S. Delpassand, Farzad Abbaspour, Yalda Salehi, Hans Jürgen Biersack, and Hojjat Ahmadzadehfar.
2022. "Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC" Cancers 14, no. 8: 1914.
https://doi.org/10.3390/cancers14081914
APA Style
Vahidfar, N., Farzanehfar, S., Abbasi, M., Mirzaei, S., Delpassand, E. S., Abbaspour, F., Salehi, Y., Biersack, H. J., & Ahmadzadehfar, H.
(2022). Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC. Cancers, 14(8), 1914.
https://doi.org/10.3390/cancers14081914